Sign in Subscribe

article

A collection of 632 issues

Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC

Skip to content The CRC Digest ◇ RESEARCH Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC Research published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops.

Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google

PET/CT metabolic parameters predict microsatellite instability status in colorectal cancer

Skip to content The CRC Digest PET/CT metabolic parameters predict microsatellite instability status in colorectal cancer Researchers developed a non-invasive nomogram model using preoperative 18F-FDG PET/CT metabolic parameters to predict MSI status in 156 CRC patients, potentially guiding personalized treatment decisions. (Rev Esp Med Nucl Imagen Mol) This

Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era

Skip to content The CRC Digest Practical management guidance for BRAF V600E-mutated mCRC in the post-BREAKWATER era A narrative review evaluates clinical integration of BRAF-targeted therapy combined with EGFR inhibition, addressing first-line treatment, MMR/MSI status, patient fitness, and sequencing strategies. (J Gastrointest Cancer) This content is informational only and

Single colonoscopy screening invitation reduces colorectal cancer incidence but not mortality at 13 years

Skip to content The CRC Digest ▪ SCREENING Single colonoscopy screening invitation reduces colorectal cancer incidence but not mortality at 13 years A long-term study found that a single colonoscopy screening invitation reduced CRC incidence compared to no invitation, but did not reduce cancer-related mortality at 13-year follow-up. (Ann Intern Med)

Discoidin Domain Receptor 1 promotes collagen alignment and immune exclusion in microsatellite stable colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Discoidin Domain Receptor 1 promotes collagen alignment and immune exclusion in microsatellite stable colorectal cancer (Cancer Res Commun) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA High-dose vitamin D3 does not improve progression-free survival in metastatic colorectal cancer The phase III SOLARIS trial found median PFS was 11.8 months with high-dose vitamin D3 (8,000 IU then 4,000 IU daily) versus 10.3 months with standard-dose

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells

Skip to content The CRC Digest Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells A Lepidium latifolium formulation induced cell death and metabolic disruption in KRAS-mutant cancer models through iron-dependent mechanisms. (Molecules) This content is informational only and does not constitute medical advice. Always consult your oncologist

Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways

Skip to content The CRC Digest Roadmap for early-onset colorectal cancer prevention highlights lifestyle factors and emerging risk pathways Review identifies obesity, metabolic conditions, poor diet, and sedentary behavior as key EOCRC risk factors, with growing evidence for early-life and gut microbial exposures. (Nature Reviews Cancer) This content is informational